NCT02892695Unknown1 期
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2016年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Adverse events attributed to the administration of the anti-CD19 CAR-NK cells
研究概览
简要总结
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
详细描述
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant. In addition, some patients who enroll to other CD19-CAR-T cell therapy trials might be eligible for this trial if their CD19-CAR-T cells cannot be produced successfully because they have insufficient T cells to allow the CD19-CAR-T cells to be made; their T cells are inefficiently transduced with CAR viruses; or their CAR-T cell expansion is failed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects with CD19+ B cell malignancies in patients who have no available curative treatment options except stem cell transplantation, with limited prognosis (several months to < 2 year survival) and no available treatment option to achieve complete remission prior to transplant. Some patients who have enrolled to other CD19-CAR-T cell therapy trials may be eligible if their CD19-CAR-T cells cannot be produced successfully because they have insufficient T cells to allow the CD19-CAR-T cells to be made; their T cells are inefficiently transduced with CAR viruses; or their CAR-T cell expansion is failed. All of those patients must meet the following criteria:
- •Eligible diseases: Acute lymphocytic leukemia (ALL), Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Mantle cell lymphoma, B-cell prolymphocytic leukemia, and diffuse large cell lymphoma, previously identified as CD19+.
- •Patients 3 years of age or older, and must have a life expectancy > 12 weeks.
- •Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than
- •Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR NK cells.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: White blood cell count (WBC) ≥ 2500c/ml, Platelets ≥ 50×10^9/L, Hb ≥ 9.0g/dL, lymphocyte (LY) ≥ 0.7×10^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and amylase < 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
- •Ability to give informed consent.
排除标准
- •Pregnant or nursing women may not participate.
- •Active HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time of screening.
- •Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
- •History of severe immediate hypersensitivity to any of the agents including cyclophosphamide, fludarabine, or aldesleukin.
- •Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- •The existence of unstable or active ulcers or gastrointestinal bleeding.
- •Patients need anticoagulant therapy (such as warfarin or heparin).
- •Patients need long-term antiplatelet therapy (aspirin at a dose > 300mg/d; clopidogrel at a dose > 75mg/d).
- •Patients using fludarabine or cladribine chemotherapy within 3 months prior to leukapheresis.
研究组 & 干预措施
CAR-NK Cell immunotherapy
Experimental
Enrolled patients will receive CAR-NK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
干预措施: anti-CD19 CAR-NK cells (Biological)
结局指标
主要结局
Adverse events attributed to the administration of the anti-CD19 CAR-NK cells
时间窗: 2 years
次要结局
- Objective Response Rate(Safety follow-up is 100 days from last CAR-NK infusion)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRelapsed Pediatric ALLRefractory Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT04888468Chongqing Precision Biotech Co., Ltd9
Unknown
1 期
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaMantle Cell LymphomaAcute Lymphocytic LeukemiaDiffuse Large Cell LymphomaB-cell Prolymphocytic LeukemiaFollicular LymphomaChronic Lymphocytic LeukemiaNCT02819583PersonGen BioTherapeutics (Suzhou) Co., Ltd.10
Unknown
1 期
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaAcute Lymphocytic LeukemiaFollicular LymphomaB-cell Prolymphocytic LeukemiaMantle Cell LymphomaDiffuse Large Cell LymphomaChronic Lymphocytic LeukemiaNCT02851589PersonGen BioTherapeutics (Suzhou) Co., Ltd.10
Unknown
1 期
CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）Leukemia, Myeloid, AcuteNCT03556982The Affiliated Hospital of the Chinese Academy of Military Medical Sciences10
Unknown
1 期
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALLAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaNCT04888442Chongqing Precision Biotech Co., Ltd18